We offer validated IHC assays for established ADC targets,including HER2,cMET,B7H3,TROP2,DLL3,EGFR,and Nectin2. We're also actively developing assays for emerging targets,including B7-H4,HER3,ROR1,CEACAM5,and STEAP1,with additional biomarkers coming soon.
"},{"faq_question":"How,and to what extent,must the ADC target be expressed on cancer cells? ","faq_answer":"Target expression is a prerequisite for ADC efficacy. The required level and pattern of expression can vary significantly depending on the ADC and the mechanism of action. CellCarta supports expression analysis across multiple platforms — including IHC,IF,flow cytometry,and mass spectrometry — to help you determine the threshold and distribution of target expression needed for your program."},{"faq_question":"What assay technologies are available? ","faq_answer":"Our ADC platform spans singleplex and multiplex IHC,multiplex immunofluorescence with up to 40 markers per slide,in-situ hybridization (ISH/RNAscope),and FISH. This multi-modal approach allows us to characterise target expression at the protein,RNA,and genomic level within the same tissue context. "},{"faq_question":"How do you assess ADC killing of target cells? ","faq_answer":"Assessing ADC killing efficiency requires evaluating multiple downstream events:target engagement,internalization,linker cleavage,and cytotoxic payload release. CellCarta uses receptor occupancy (RO) assays and transcriptomic approaches (RNAseq,CITE-seq) to indirectly assess binding efficiency and payload activity across both solid and non-solid tumors."},{"faq_question":"Does ADC have on-target,off-tumor effects? ","faq_answer":"Identifying on-target,off-tumor toxicity early is critical for safe ADC development. Our mIF and mIHC platforms evaluate target expression in normal tissues,while flow cytometry tracks circulating target-expressing cell counts as a surrogate for off-target killing. Bulk RNA sequencing and gene set enrichment analysis (GSEA) further investigate activated toxicity pathways. "}];oxy-supreme-cellcarta-cta-banner-items-data:[{"faq_question":"What ADC biomarkers do you support?","faq_answer":"We offer validated IHC assays for established ADC targets,including HER2,cMET,B7H3,TROP2,DLL3,EGFR,and Nectin2. We're also actively developing assays for emerging targets,including B7-H4,HER3,ROR1,CEACAM5,and STEAP1,with additional biomarkers coming soon.
"},{"faq_question":"How,and to what extent,must the ADC target be expressed on cancer cells? ","faq_answer":"Target expression is a prerequisite for ADC efficacy. The required level and pattern of expression can vary significantly depending on the ADC and the mechanism of action. CellCarta supports expression analysis across multiple platforms — including IHC,IF,flow cytometry,and mass spectrometry — to help you determine the threshold and distribution of target expression needed for your program."},{"faq_question":"What assay technologies are available? ","faq_answer":"Our ADC platform spans singleplex and multiplex IHC,multiplex immunofluorescence with up to 40 markers per slide,in-situ hybridization (ISH/RNAscope),and FISH. This multi-modal approach allows us to characterise target expression at the protein,RNA,and genomic level within the same tissue context. "},{"faq_question":"How do you assess ADC killing of target cells? ","faq_answer":"Assessing ADC killing efficiency requires evaluating multiple downstream events:target engagement,internalization,linker cleavage,and cytotoxic payload release. CellCarta uses receptor occupancy (RO) assays and transcriptomic approaches (RNAseq,CITE-seq) to indirectly assess binding efficiency and payload activity across both solid and non-solid tumors."},{"faq_question":"Does ADC have on-target,off-tumor effects? ","faq_answer":"Identifying on-target,off-tumor toxicity early is critical for safe ADC development. Our mIF and mIHC platforms evaluate target expression in normal tissues,while flow cytometry tracks circulating target-expressing cell counts as a surrogate for off-target killing. Bulk RNA sequencing and gene set enrichment analysis (GSEA) further investigate activated toxicity pathways. "}]}#-supreme-cellcarta-faq-13-144{items-data:[{"faq_question":"What ADC biomarkers do you support?","faq_answer":"We offer validated IHC assays for established ADC targets,including HER2,cMET,B7H3,TROP2,DLL3,EGFR,and Nectin2. We're also actively developing assays for emerging targets,including B7-H4,HER3,ROR1,CEACAM5,and STEAP1,with additional biomarkers coming soon.
"},{"faq_question":"How,and to what extent,must the ADC target be expressed on cancer cells? ","faq_answer":"Target expression is a prerequisite for ADC efficacy. The required level and pattern of expression can vary significantly depending on the ADC and the mechanism of action. CellCarta supports expression analysis across multiple platforms —including IHC and IF,flow cytometry,and mass spectrometry —to help you determine the threshold and distribution of target expression needed for your program.
"},{"faq_question":"What assay technologies are available? ","faq_answer":"Our ADC spans singleplex and mIHC,mIF with up to 40 markers per slide,in situ hybridization (ISH/RNAscope),and mass spectrometry. This multi-modal approach allows us to characterize target expression at the protein,RNA,and genomic level within the same tissue context,supporting the advancement of your program’s ADC platform.
"},{"faq_question":"How do you assess ADC killing of target cells? ","faq_answer":"Assessing ADC killing efficiency requires evaluating multiple downstream events:target engagement,internalization,linker cleavage,and cytotoxic payload release. CellCarta uses various assays,including receptor occupancy (RO) assays,and approaches (RNAseq,CITE-seq) to assess both binding efficiency and payload activity across tissue and liquid samples.
"},{"faq_question":"Does ADC have on-target,off-tumor effects? ","faq_answer":"Identifying on-target,off-tumor toxicity early is critical for safe ADC platform development. Our mIF and mIHC platforms evaluate target expression in normal tissues,while flow cytometry tracks circulating target-expressing cell counts as a surrogate for off-target killing. Bulk RNA sequencing and gene set enrichment analysis (GSEA) further investigate activated toxicity pathways.
"}]}#-supreme-cellcarta-featured-resources-16-144{cards-data:[{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"},{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar-2.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"},{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar-3.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"}]}#-supreme-cellcarta-infobox-24-176{tabs-data:[{"tab_title":"Confirm Target Engagement ","content_title":"","content_body":"Depending on your study,we can incorporate multiple ADC assays to measure target engagement.
\nReceptor occupancy assays and transcriptomic analysis confirm target binding,with continuous image scoring and analysis for clinical endpoints. For early-stage programs,we also support reagent-free mass spectrometry.
\nImmunohistochemistry (IHC) assays can assess expression in solid tumor tissue,while flow cytometry is suited for liquid biopsies.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Validate-Target-Engagement-133.jpg","image_alt":""},{"tab_title":"Map the TME","content_title":"","content_body":"We can support mapping of the tumor microenvironment (TME),critical for understanding patient response to ADC platforms.
\nTo assess immune cell populations and guide patient selection,we can use various platforms,such as multiplex IHC,CITE-seq,bulk RNAseq,and flow cytometry.
\nOur advanced spatial platforms —Visium,GeoMx,COMET —can layer in added proteomic and genomic analysis to explore cellular phenotype,distribution,and function.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/Lunaphore-COMET.png","image_alt":""},{"tab_title":"Track Stability and Toxicity","content_title":"","content_body":"Track ADC stability and concentration through our advanced mass spectrometry-based workflow,capable of supporting all stages of therapeutic development.
\nFor toxicity,we can assess target expression in normal tissues via mIF and mIHC,track circulating target expressing cells by flow cytometry,and investigate toxicity pathways through bulk RNA sequencing and gene set enrichment analysis.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Manage-Toxicity-96.jpg","image_alt":""},{"tab_title":"Biobank and Global Presence","content_title":"","content_body":"Accelerate assay development and validation with access to our regulated Biobank,containing over 5,000 consent confirmed and quality checked FFPE and blood samples. This enables immediate study initiation without delay.
\nWhen your ADC platform program is ready to scale,our fully owned and accredited laboratory network across the US,Canada,Belgium,China,and Australia gives you standardized workflows and end-to-end CDx services globally.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Biobank-176.jpg","image_alt":""}];oxy-supreme-cellcarta-infobox-tabs-data:[{"tab_title":"Confirm Target Engagement ","content_title":"","content_body":"Depending on your study,we can incorporate multiple ADC assays to measure target engagement.
\nReceptor occupancy assays and transcriptomic analysis confirm target binding,with continuous image scoring and analysis for clinical endpoints. For early-stage programs,we also support reagent-free mass spectrometry.
\nImmunohistochemistry (IHC) assays can assess expression in solid tumor tissue,while flow cytometry is suited for liquid biopsies.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Validate-Target-Engagement-133.jpg","image_alt":""},{"tab_title":"Map the TME","content_title":"","content_body":"We can support mapping of the tumor microenvironment (TME),critical for understanding patient response to ADC platforms.
\nTo assess immune cell populations and guide patient selection,we can use various platforms,such as multiplex IHC,CITE-seq,bulk RNAseq,and flow cytometry.
\nOur advanced spatial platforms —Visium,GeoMx,COMET —can layer in added proteomic and genomic analysis to explore cellular phenotype,distribution,and function.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/Lunaphore-COMET.png","image_alt":""},{"tab_title":"Track Stability and Toxicity","content_title":"","content_body":"Track ADC stability and concentration through our advanced mass spectrometry-based workflow,capable of supporting all stages of therapeutic development.
\nFor toxicity,we can assess target expression in normal tissues via mIF and mIHC,track circulating target expressing cells by flow cytometry,and investigate toxicity pathways through bulk RNA sequencing and gene set enrichment analysis.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Manage-Toxicity-96.jpg","image_alt":""},{"tab_title":"Biobank and Global Presence","content_title":"","content_body":"Accelerate assay development and validation with access to our regulated Biobank,containing over 5,000 consent confirmed and quality checked FFPE and blood samples. This enables immediate study initiation without delay.
\nWhen your ADC platform program is ready to scale,our fully owned and accredited laboratory network across the US,Canada,Belgium,China,and Australia gives you standardized workflows and end-to-end CDx services globally.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Biobank-176.jpg","image_alt":""}]}#-supreme-cellcarta-service-blocks-45-176{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Sample-Logistics-tab-408.jpg","image_alt":"","title":"Sample Logistics","description":"Global sample management,transport,and biorepository services with real-time tracking. ","button_text":"Explore Sample Logistics","button_url":"/clinical-trial-services/sample-logistics/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/21-Biomarker-Solutions-Hero.jpg","image_alt":"","title":"Biomarker Solutions ","description":"Multi-platform biomarker strategies from discovery through clinical development. ","button_text":"Explore Biomarker Solutions","button_url":"/capabilities/biomarkers/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/CDx-Development-hero-64.jpg","image_alt":"","title":"CDx Development ","description":"Advance clinical trial assays into approved,commercially viable CDx programs with unmatched flexibility. ","button_text":"Explore CDx solutions","button_url":"/clinical-trial-services/cdx-development/","button_target":"_self"}]}#-supreme-cellcarta-tab-content-11-144{tabs-data:[{"tab_title":"Confirm Target Engagement ","content_title":"","content_body":"Depending on your study,we can incorporate multiple ADC assays to measure target engagement.
\nReceptor occupancy assays and transcriptomic analysis confirm target binding,with continuous image scoring and analysis for clinical endpoints. For early-stage programs,we also support reagent-free mass spectrometry.
\nImmunohistochemistry (IHC) assays can assess expression in solid tumor tissue,while flow cytometry is suited for liquid biopsies.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Validate-Target-Engagement-133.jpg","image_alt":""},{"tab_title":"Map the TME","content_title":"","content_body":"We can support mapping of the tumor microenvironment (TME),critical for understanding patient response to ADC platforms.
\nTo assess immune cell populations and guide patient selection,we can use various platforms,such as multiplex IHC,CITE-seq,bulk RNAseq,and flow cytometry.
\nOur advanced spatial platforms —Visium,GeoMx,COMET —can layer in added proteomic and genomic analysis to explore cellular phenotype,distribution,and function.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/Lunaphore-COMET.png","image_alt":""},{"tab_title":"Track Stability and Toxicity","content_title":"","content_body":"Track ADC stability and concentration through our advanced mass spectrometry-based workflow,capable of supporting all stages of therapeutic development.
\nFor toxicity,we can assess target expression in normal tissues via mIF and mIHC,track circulating target expressing cells by flow cytometry,and investigate toxicity pathways through bulk RNA sequencing and gene set enrichment analysis.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Manage-Toxicity-96.jpg","image_alt":""},{"tab_title":"Biobank and Global Presence","content_title":"","content_body":"Accelerate assay development and validation with access to our regulated Biobank,containing over 5,000 consent confirmed and quality checked FFPE and blood samples. This enables immediate study initiation without delay.
\nWhen your ADC platform program is ready to scale,our fully owned and accredited laboratory network across the US,Canada,Belgium,China,and Australia gives you standardized workflows and end-to-end CDx services globally.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Biobank-176.jpg","image_alt":""}]}